J. Elliott

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

D. Esseltine, K. Anderson, P. Sonneveld, 2017, British journal of haematology.

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

J. Reeves, I. Flinn, R. Neuwirth, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center

Michael Knauss, S. Peasah, J. Elliott, 2019, Journal of Thrombosis and Thrombolysis.

Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability?

W. Chandler, M. Meissner, J. Elliott, 2003, The Journal of trauma.

Fat embolism syndrome: Experience from an Australian trauma centre

A. Kirk, D. Varma, L. Kimmel, 2020 .

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

M. Dimopoulos, A. Palumbo, P. Richardson, 2015, American journal of hematology.

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

A. Palumbo, R. Hájek, A. Larocca, 2021, Blood Cancer Journal.

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.

N. Puig, M. Boccadoro, R. Hájek, 2021, Future oncology.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

D. Esseltine, P. Sonneveld, S. Lonial, 2013 .

Medication Errors Associated With Anticoagulant Therapy in the Hospital

S. Suga, K. Hosoda, K. Nakao, 2004 .

Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.

Ioana R. Bonta, K. Leventakos, A. Dimou, 2023, Journal of Clinical Oncology.